Clinical trials: Normal Population
Renal Impairment
Study of Sulthiame (S-054502) in Participants With Renal Impairment and Matched Healthy Controls
The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of sulthiame in participants with mild and moderate renal impairment compared to those in healthy participants with normal renal…
- Trial name
- NCT07857837
- Testing
- Sulthiame
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Shionogi
Common Warts
A Study of A-101 Solution in Subjects With Common Warts.
This is a randomized, double-blind, vehicle-controlled, parallel-group study with 3 treatment groups.
- Trial name
- NCT02669862
- Testing
- A-101 Solution 40, A-101 Solution 45, Vehicle Solution
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Aclaris Therapeutics, Inc.
Carcinoid Syndrome, Carcinoid
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to…
- Conditions
- Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
- Trial name
- CAREFNDR (NCT07087054)
- Testing
- Paltusotine
- Where
- 72 sites in United States, Argentina and 12 more
- Volunteers
- 141 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Atopic Dermatitis
Study of 0417 Ointment in the Treatment of Atopic Dermatitis
The aim of this trial is to assess the efficacy of 0417 Ointment in the Treatment of Atopic Dermatitis. Treatment medication will be administered as follows: Apply a thin layer of ointment to affected skin areas twice daily and…
- Trial name
- NCT01139450
- Testing
- 0417, Vehicle of 0417 test product, Tacrolimus Ointment 0.03%
- Where
- United States
- Volunteers
- 899 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Breast Cancer, Breast Diseases
Real World Evaluation of Lunit INSIGHT MMG Technology
This study is a single-centre prospective observational cohort study designed to assess and compare the sensitivity and specificity of a Lunit INSIGHT MMG assisted human reading to the standard care double human reading process…
- Trial name
- NCT06232070
- Testing
- Lunit INSIGHT MMG
- Where
- United Kingdom
- Volunteers
- 5,500 people
- Sponsor
- Lunit Inc.
Healthy Volunteers
Assessment of Pharmacokinetics (PK) and Safety of M834 and Orencia ®, in Healthy Subjects
The purpose of this study is assess the pharmacokinetics and safety of M834 and Orencia ® following administration of a single-dose in healthy volunteers.
- Trial name
- NCT02923583
- Testing
- M834, US-Sourced Orencia®, EU-Sourced Orencia®
- Where
- 2 sites in United Kingdom
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- Momenta Pharmaceuticals, Inc.
Actinic Keratosis
Bioequivalence Study of Two Imiquimod Cream 5%
The primary objectives are to establish the therapeutic equivalence of imiquimod cream 5%, manufactured by Taro Pharmaceuticals Inc.
- Trial name
- NCT00828568
- Testing
- Imiquimod 5% manufactured by Taro, Aldara - Imiquimod 5%, Imiquimod Vehicle manufactured by Taro
- Where
- 20 sites in United States
- Volunteers
- 425 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Tinea Pedis, Athlete's Foot
Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis
This is a study of the safety and efficacy of Econazole Nitrate Foam 1% and the Foam Vehicle in subjects with interdigital tinea pedis (athlete's foot between the toes).
- Trial name
- NCT01358240
- Testing
- Econazole Nitrate Foam 1%, Vehicle Foam, Econazole Nitrate Cream 1%
- Where
- 12 sites in United States
- Volunteers
- 336 people
- Sponsor
- AmDerma
Long QT Syndrome
Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of eleclazine and its metabolite, GS-623134, in participants with normal and impaired renal function.
- Trial name
- NCT02441829
- Testing
- Eleclazine
- Where
- 7 sites in United States, Moldova and 1 more
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Acne Vulgaris
Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris
Bioequivalence with Clinical Endpoints.
- Trial name
- NCT02709902
- Testing
- Adapalene/BP gel, 0.3%/2.5%, EPIDUO® FORTE
- Volunteers
- 460 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Purpura, Thrombocytopaenic, Idiopathic
Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag
This study is designed to investigate the safety profile and the photoirritant potential of eltrombopag in healthy subjects. The study is placebo- and positive controlled, randomized, parallel group with three treatment arms…
- Trial name
- NCT00688272
- Testing
- Ciprofloxacin, Eltrombopag
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetic Foot Ulcers
Phase IV Study to Evaluate the Efficacy of AMNIOEXCEL in Diabetic Foot Ulcers
The primary goal of the study is to demonstrate the increased rate of complete wound closure by AMNIOEXCEL® compared to routine care in patients with chronic diabetic foot ulcers
- Trial name
- NCT02209051
- Testing
- AMNIOEXCEL, Standard of Care, Diabetic Foot Ulcers
- Where
- 8 sites in United States
- Volunteers
- 29 people
- Sponsor
- Integra LifeSciences Corporation
Hidradenitis Suppurativa
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
- Trial name
- BE HEARD EXT (NCT04901195)
- Testing
- Bimekizumab
- Where
- 145 sites in United States, Australia and 17 more
- Volunteers
- 658 people
- Sponsor
- UCB Biopharma SRL
Acute Intermittent Porphyria
Porphozym in the Treatment of Acute Attacks in AIP
A multi-centre, double-blind, randomized, placebo controlled, parallel group trial, investigating the efficacy and safety of Porphozym (recombinant human porphobilinogen deaminase)in the treatment of acute attacks in AIP.
- Trial name
- NCT00418795
- Testing
- recombinant human porphobilinogen deaminase (Porphozym)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Zymenex A/S
Atopic Dermatitis
Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age
This clinical study is designed to test how well a medicine called abrocitinib works and how safe it is for young children (ages 2 to under 6) who have moderate-to-severe eczema (also known as atopic dermatitis).Eczema is a skin…
- Trial name
- NCT07823595
- Testing
- Abrocitinib
- Volunteers
- 90 people
- Sponsor
- Pfizer
Psoriatic Arthritis
Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis
This is a multicenter, double-blind, randomized, parallel-group study to compare the efficacy,pharmacodynamics (PD), pharmacokinetics (PK), safety, and immunogenicity of BAT2506 versus Simponi® in participants with active PsA.
- Trial name
- NCT05046431
- Testing
- BAT2506, EU Simponi
- Where
- China
- Volunteers
- 704 people
- Sponsor
- Bio-Thera Solutions
Onychomycosis
Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis
This study will evaluate the efficacy, safety and tolerability of topical 10% terbinafine hydrogen chloride applied daily versus 5% amorolfine nail lacquer applied twice a week in patients with mild to moderate toenail…
- Trial name
- NCT00459537
- Testing
- terbinafine hydrogen chloride, amorolfine nail lacquer
- Where
- 10 sites in Finland, France and 8 more
- Volunteers
- 1,029 people
- Sponsor
- Novartis
Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria
A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)
THB335-201 is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adults with CSU who remain symptomatic despite standard-of-care treatment.
- Trial name
- NCT07766499
- Testing
- THB335 Lower Dose, THB335 Higher Dose
- Where
- 15 sites in United States
- Volunteers
- 81 people
- Sponsor
- Calixis Inc.
Psoriasis
BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study
Systemic safety following single and multiple dermal administration of BAY1003803
- Trial name
- NCT02936492
- Testing
- BAY1003803 0.01% lipophilic cream, BAY1003803 0.1% lipophilic cream, BAY1003803 0.01% ointment
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bayer
Long QT Syndrome
Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function
The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of oral eleclazine and its metabolite, GS-623134, in participants with normal and impaired hepatic function.
- Trial name
- NCT02412098
- Testing
- Eleclazine
- Where
- 7 sites in United States, Germany and 2 more
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.